{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:58:44Z","timestamp":1789095524057,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","award":["20100490"],"award-info":[{"award-number":["20100490"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["258536"],"award-info":[{"award-number":["258536"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001260","name":"National Organization for Rare Disorders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004785","name":"Nordforsk","doi-asserted-by":"publisher","award":["70945"],"award-info":[{"award-number":["70945"]}],"id":[{"id":"10.13039\/501100004785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011112","name":"UCB Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2011\/2069-31\/4"],"award-info":[{"award-number":["2011\/2069-31\/4"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010135","name":"Finnish Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006310","name":"Medicinska Forskningsr\u00e5det","doi-asserted-by":"publisher","award":["2015-00891_5"],"award-info":[{"award-number":["2015-00891_5"]}],"id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006310","name":"Medicinska Forskningsr\u00e5det","doi-asserted-by":"publisher","award":["D0342301"],"award-info":[{"award-number":["D0342301"]}],"id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006310","name":"Medicinska Forskningsr\u00e5det","doi-asserted-by":"publisher","award":["C0634901"],"award-info":[{"award-number":["C0634901"]}],"id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ard.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T13:50:45Z","timestamp":1743947445000},"page":"937-948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate\/sulfasalazine\/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-6818","authenticated-orcid":false,"given":"Merete Lund","family":"Hetland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1104-7755","authenticated-orcid":false,"given":"Marte S.","family":"Heiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6972-5603","authenticated-orcid":false,"given":"Tuulikki","family":"Sokka-Isler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-1276","authenticated-orcid":false,"given":"Anna","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1427-4745","authenticated-orcid":false,"given":"Espen","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0179-9478","authenticated-orcid":false,"given":"Jarno","family":"Rutanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6751-3330","authenticated-orcid":false,"given":"Gerdur","family":"Grondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-6831","authenticated-orcid":false,"given":"Lykke Midtb\u00f8ll","family":"\u00d8rnbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5144","authenticated-orcid":false,"given":"Pernille","family":"B\u00f8yesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7856-3968","authenticated-orcid":false,"given":"Jon","family":"Lampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-1934","authenticated-orcid":false,"given":"Michael","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-6505","authenticated-orcid":false,"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-9552","authenticated-orcid":false,"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0211-9238","authenticated-orcid":false,"given":"Aulikki","family":"Kononoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5037-5546","authenticated-orcid":false,"given":"Kristina","family":"Lend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2877-1582","authenticated-orcid":false,"given":"Simon","family":"Krabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-5873","authenticated-orcid":false,"given":"Inge C.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-6283","authenticated-orcid":false,"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5475-7610","authenticated-orcid":false,"given":"Kim","family":"H\u00f8rslev-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.03.002_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.03.002_bib0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","article-title":"Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial","volume":"156","author":"Bakker","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.03.002_bib0004","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/annrheumdis-2013-205143","article-title":"Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial","volume":"74","author":"ter Wee","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/art.21796","volume":"54","author":"Hetland","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/ard.2009.125534","article-title":"Radiographic progression and remission rates in early rheumatoid arthritis\u2014MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial","volume":"69","author":"Hetland","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0008","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/annrheumdis-2015-208166","article-title":"Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)","volume":"75","author":"H\u00f8rslev-Petersen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0009","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","volume":"73","author":"H\u00f8rslev-Petersen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1136\/annrheumdis-2013-203497","volume":"73","author":"Rantalaiho","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0011","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/acr.23782","article-title":"Early targeted combination treatment with conventional synthetic disease-modifying antirheumatic drugs and long-term outcomes in rheumatoid arthritis: ten-year follow-up results of a randomized clinical trial","volume":"71","author":"Rantalaiho","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.03.002_bib0012","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group","volume":"353","author":"M\u00f6tt\u00f6nen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.03.002_bib0013","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13063-017-1891-x","volume":"18","author":"Glinatsi","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.ard.2025.03.002_bib0014","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.03.002_bib0015","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0016","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.03.002_bib0017","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2012-201491","article-title":"Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index","volume":"71","author":"Aletaha","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0018","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League against rheumatism preliminary definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.03.002_bib0020","series-title":"Medical dictionary for regulatory activities [Internet]","year":"2024"},{"key":"10.1016\/j.ard.2025.03.002_bib0021","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/ard.2007.076307","article-title":"Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study","volume":"67","author":"Hetland","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0022","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2011-200632","article-title":"Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP","volume":"71","author":"Hetland","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0023","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard-2023-223977","article-title":"Three-month tapering and discontinuation of long-term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial","volume":"82","author":"Almayali","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.03.002_bib0024","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","article-title":"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial","volume":"396","author":"Burmester","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.03.002_bib0025","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group","volume":"333","author":"Kirwan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.03.002_bib0026","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/art.21298","article-title":"Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial","volume":"52","author":"Svensson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.03.002_bib0027","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bone.2018.06.008","article-title":"The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials","volume":"114","author":"Blavnsfeldt","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.ard.2025.03.002_bib0028","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/eurheartj\/eht071","article-title":"International differences in treatment effect: do they really exist and why?","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ard.2025.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:10:37Z","timestamp":1774415437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725008192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0003496725008192"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.03.002","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate\/sulfasalazine\/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}